Biogen Idec and Elan Corporation, plc have announced new data on the global utilization, safety and overall patient exposure of TYSABRI® ((natalizumab); humanized by MRCT). “These data suggest that neurologists and patients are increasingly choosing TYSABRI for the treatment of their disease.” Click here to read the full article on PharmaLive.